Safety, tolerability, pharmacokinetic, and pharmacodynamic characteristics of vutiglabridin: A first‐in‐class, first‐in‐human study

This study aimed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of vutiglabridin, a potential anti‐obesity treatment under development, for the first time in humans. A randomized, placebo‐controlled, single‐ and multiple‐ascending dose study (SAD and MAD, respectively)...

Descripción completa

Detalles Bibliográficos
Autores principales: Na, Joo Young, Yoon, Deok Yong, Yoo, Hyounggyoon, Lee, SeungHwan, Yu, Kyung‐Sang, Jang, In‐Jin, Yoo, Sang‐Ku, Kim, Youngah, Oh, Jaeseong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652434/
https://www.ncbi.nlm.nih.gov/pubmed/36176051
http://dx.doi.org/10.1111/cts.13401

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652434/
https://www.ncbi.nlm.nih.gov/pubmed/36176051
http://dx.doi.org/10.1111/cts.13401

Ejemplares similares